Win-win international collaborations
Strategic partnership agreements with universities, research centres, and companies worldwide make up one of the pillars of Iproteos. The company applies IPROTech to design innovative peptidomimetic drugs to treat a wide range of diseases.
Of note are the following: a technology transfer agreement with the University of Barcelona and IRB Barcelona; a partnership agreement with CIBERSAM and the University of the Basque Country to evaluate the first drug for the treatment of cognitive impairment associated with schizophrenia (CIAS); and participation in a European Commission Horizon 2020 consortium for the development of drugs to treat epilepsy.
If you are interested in collaborating with Iproteos, please contact us.